Except for Payment of DRG in Beijing, medicine recovers!Medical Devices ETF (159883) rose 1.63 % in early trading

On July 14, the three major indexes rose and declined. Affected by Beijing's trial DRG, the pharmaceutical medical rebounded strongly, and the concept of selection of monkey acne and medical equipment rose. In terms of individual stocks, Zhijiang Biological and Opangshi rose 7.86%and 7.40%, respectively, and Ai Bo Medical rose 5.78%. South Micro -Medicine, Huitai Medical, Antu Bio, Heartai Medical, etc. rose.

As of press time, ETF (159883), the largest A -share scale, rose by 1.63 % in early trading, with real -time transaction turnover exceeding 21 million yuan.

On the news, yesterday, the Beijing Municipal Medical Insurance Bureau issued the "Notice of the Administrative Measures for CHS-DRG Pay New Medicine New Technology Payment (Trial)" and decided to try the management measures for the CHS-DRG payment new drug and new technology ". The equipment and diagnosis and treatment items can not be paid according to the DRG. This time the Beijing Medical Insurance Bureau's management measures on the new technologies of CHS-DRG payment new technologies are the substantial encouragement measures for innovative drugs and services. Advantages are of great significance to paying ceiling for the innovative pharmaceutical and device industry worried about the market.

In this regard, Guojin Securities believes that except for the payment mechanism is expected to further boost the enthusiasm of innovative technology. When implementing the traditional DRG payment system, there are special cases such as special cases, high -cost service projects and technological innovation projects, so that the level of treatment costs or resource consumption is much higher than the average level of the same group of cases. Except for these projects in the DRG payment system, it is expected to overcome the pain points of the traditional DRG payment system, improve the homogeneity of the resource consumption of the DRG disease group, make innovative medical projects or products more economical, and use the medical insurance fund reasonably. At the same time, further help the development of innovative technology, and benefit innovative pharmaceuticals and equipment companies and the innovation industry chain.

Tianfeng Securities Medical Yang Song team also said that the core of medical insurance still encourages innovation, the medical insurance conclusion balance improves, and the amount of money with volume purchases is good, and in the end it will be spent.

According to statistics, as of the end of the first quarter of this year, the public fund holding of pharmaceuticals has also been at a low point in the past ten years. The public offering positions after deducting active pharmaceutical funds and index funds are currently only about 7%. Suddenly increase the need to investigate pharmaceutical stocks or reflect the replenishment of positions.

In fact, the medical device sector has continued to call for more than a year, and the valuation has reached a historical low. Data show that the latest valuation of the ETF target index of the medical device is only 20.43 times, which is lower than the time interval of more than 99%of history. It is also lower than that of CSI Medical, CSI 300 Medicine, etc., and the cost performance is prominent.

It is understood that the medical device ETF (159883) is currently the largest A -share medical device industry ETF. The ETF tracking CSI refers to the medical device index, one refers to the four major sections of medical equipment, high and low -value consumables, IVDs, and medical beauty, covering the leading stocks of science and innovation boards, GEM, and motherboard medical equipment. develop.

The dual -innovation content is about 70 %. The subject index of the target index contains 52 science and technology boards+GEM stocks, which accounts for 71.34%. The investment threshold for investment in science and technology boards and GEM is high, and high -priced stocks. In comparison, the medical device ETF can open a securities account to perform efficient transactions, and it only costs about 70 yuan in one hand. It is more suitable for ordinary investors.

The general trend of medical new infrastructure. New medical infrastructure is a major trend in the construction of a national medical system. It is even more valued under the background of domestic medical shortcomings (tight medical resources) under the impact of the overall environment. Strengthen public health construction worldwide, conform to the wave of new medical infrastructure, and provide development opportunities for domestic medical device products to go to sea. The domestic alternative of the medical device industry and the continuous acceleration of the internationalization process.

Double cover in the field. For ordinary investors, the types of medical devices are complicated and the research threshold is high, the stocks fluctuate is large, the research of individual investors is more difficult, the borrowing index fund is more worry -free, and the investment risk of individual stocks can be decentralized. Users can use medical devices ETF (159883), and out -of -the -venue users can make batch layouts through the connection fund (A share 013415, C share 013416).

- END -